Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFR3B mRNA | CTD | PMID:22079256 | 17beta-estradiol | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [Estradiol co-treated with TGFB1 protein] results in increased expression of EFR3B mRNA and EGF protein inhibits the reaction [Estradiol results in decreased expression of EFR3B mRNA] | CTD | PMID:24758408 and PMID:30165855 | 17beta-estradiol | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Estradiol results in increased expression of EFR3B mRNA | CTD | PMID:31614463 | 17beta-estradiol | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Estradiol results in decreased expression of EFR3B mRNA | CTD | PMID:24758408 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Efr3b (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of EFR3B mRNA | CTD | PMID:19465110 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of EFR3B mRNA | CTD | PMID:33387578 | 2-hydroxypropanoic acid | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of EFR3B mRNA | CTD | PMID:30851411 | 4,4'-sulfonyldiphenol | affects methylation | ISO | Efr3b (Mus musculus) | 6480464 | bisphenol S affects the methylation of EFR3B gene | CTD | PMID:31683443 | 4-hydroxyphenyl retinamide | increases expression | ISO | Efr3b (Mus musculus) | 6480464 | Fenretinide results in increased expression of EFR3B mRNA | CTD | PMID:28973697 | 5-aza-2'-deoxycytidine | affects expression | ISO | EFR3B (Homo sapiens) | 6480464 | Decitabine affects the expression of EFR3B mRNA | CTD | PMID:23300844 | aflatoxin B1 | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased expression of EFR3B mRNA | CTD | PMID:21641981 | aflatoxin B1 | increases methylation | ISO | EFR3B (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased methylation of EFR3B gene and Aflatoxin B1 results in increased methylation of EFR3B intron | CTD | PMID:27153756 and PMID:30157460 | Aflatoxin B2 alpha | affects methylation | ISO | EFR3B (Homo sapiens) | 6480464 | aflatoxin B2 affects the methylation of EFR3B intron | CTD | PMID:30157460 | amphotericin B | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Amphotericin B analog results in increased expression of EFR3B mRNA | CTD | PMID:28534445 | atrazine | affects methylation | EXP | | 6480464 | Atrazine affects the methylation of EFR3B gene | CTD | PMID:35440735 | benzo[a]pyrene | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of EFR3B mRNA | CTD | PMID:20064835 more ... | benzo[a]pyrene | affects methylation | ISO | EFR3B (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of EFR3B intron | CTD | PMID:30157460 | benzo[a]pyrene | increases methylation | ISO | EFR3B (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of EFR3B promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases expression | ISO | Efr3b (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of EFR3B mRNA | CTD | PMID:32417428 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:26238291 | benzo[e]pyrene | increases methylation | ISO | EFR3B (Homo sapiens) | 6480464 | benzo(e)pyrene results in increased methylation of EFR3B intron | CTD | PMID:30157460 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Diethylhexyl Phthalate results in decreased expression of EFR3B mRNA | CTD | PMID:31163220 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of EFR3B mRNA | CTD | PMID:25181051 | bisphenol A | decreases expression | ISO | Efr3b (Mus musculus) | 6480464 | bisphenol A results in decreased expression of EFR3B mRNA | CTD | PMID:32156529 and PMID:38074096 | butanal | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | butyraldehyde results in increased expression of EFR3B mRNA | CTD | PMID:26079696 | cantharidin | decreases expression | ISO | Efr3b (Mus musculus) | 6480464 | Cantharidin results in decreased expression of EFR3B mRNA | CTD | PMID:36907384 | carbon nanotube | increases expression | ISO | Efr3b (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | choline | multiple interactions | ISO | Efr3b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of EFR3B gene | CTD | PMID:20938992 | chromium(6+) | affects expression | ISO | Efr3b (Mus musculus) | 6480464 | chromium hexavalent ion affects the expression of EFR3B mRNA | CTD | PMID:28472532 | cisplatin | affects expression | ISO | EFR3B (Homo sapiens) | 6480464 | Cisplatin affects the expression of EFR3B mRNA | CTD | PMID:23300844 | dichloroacetic acid | decreases expression | ISO | Efr3b (Mus musculus) | 6480464 | Dichloroacetic Acid results in decreased expression of EFR3B mRNA | CTD | PMID:28962523 | dioxygen | multiple interactions | ISO | Efr3b (Mus musculus) | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of EFR3B mRNA | CTD | PMID:30529165 | dorsomorphin | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ethanol | affects splicing | ISO | Efr3b (Mus musculus) | 6480464 | Ethanol affects the splicing of EFR3B mRNA | CTD | PMID:30319688 | folic acid | multiple interactions | ISO | Efr3b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of EFR3B gene | CTD | PMID:20938992 | FR900359 | affects phosphorylation | ISO | EFR3B (Homo sapiens) | 6480464 | FR900359 affects the phosphorylation of EFR3B protein | CTD | PMID:37730182 | L-methionine | multiple interactions | ISO | Efr3b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of EFR3B gene | CTD | PMID:20938992 | lead(0) | affects expression | ISO | EFR3B (Homo sapiens) | 6480464 | Lead affects the expression of EFR3B mRNA | CTD | PMID:28903495 | lipopolysaccharide | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of EFR3B mRNA | CTD | PMID:35811015 | lipopolysaccharide | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Lipopolysaccharides results in decreased expression of EFR3B mRNA | CTD | PMID:35811015 | maneb | multiple interactions | ISO | Efr3b (Mus musculus) | 6480464 | [Maneb co-treated with Paraquat] results in increased expression of EFR3B mRNA | CTD | PMID:36117858 | methapyrilene | increases methylation | ISO | EFR3B (Homo sapiens) | 6480464 | Methapyrilene results in increased methylation of EFR3B intron | CTD | PMID:30157460 | methoxychlor | affects methylation | EXP | | 6480464 | Methoxychlor affects the methylation of EFR3B gene | CTD | PMID:35440735 | paracetamol | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of EFR3B mRNA | CTD | PMID:26497421 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of EFR3B mRNA | CTD | PMID:33387578 | paraquat | multiple interactions | ISO | Efr3b (Mus musculus) | 6480464 | [Maneb co-treated with Paraquat] results in increased expression of EFR3B mRNA | CTD | PMID:36117858 | perfluorohexanesulfonic acid | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | perfluorohexanesulfonic acid results in increased expression of EFR3B mRNA | CTD | PMID:25812627 | perfluorononanoic acid | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | perfluoro-n-nonanoic acid results in increased expression of EFR3B mRNA | CTD | PMID:25812627 | perfluorooctanoic acid | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | perfluorooctanoic acid results in increased expression of EFR3B mRNA | CTD | PMID:25812627 | phenylmercury acetate | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of EFR3B mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFR3B mRNA | CTD | PMID:27188386 | potassium chromate | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of EFR3B mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFR3B mRNA | CTD | PMID:22079256 | propanal | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | propionaldehyde results in increased expression of EFR3B mRNA | CTD | PMID:26079696 | rac-lactic acid | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of EFR3B mRNA | CTD | PMID:30851411 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of EFR3B mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Silicon Dioxide analog results in increased expression of EFR3B mRNA | CTD | PMID:25895662 | sodium arsenite | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | sodium arsenite results in increased expression of EFR3B mRNA | CTD | PMID:34032870 | sulforaphane | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | sulforaphane results in decreased expression of EFR3B mRNA | CTD | PMID:31838189 | tamoxifen | increases expression | ISO | Efr3b (Mus musculus) | 6480464 | Tamoxifen results in increased expression of EFR3B mRNA | CTD | PMID:25123088 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of EFR3B mRNA | CTD | PMID:31150632 | titanium dioxide | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | titanium dioxide results in decreased expression of EFR3B mRNA | CTD | PMID:34973136 | trichostatin A | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of EFR3B mRNA | CTD | PMID:24935251 | triptonide | increases expression | ISO | Efr3b (Mus musculus) | 6480464 | triptonide results in increased expression of EFR3B mRNA | CTD | PMID:33045310 | urethane | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Urethane results in increased expression of EFR3B mRNA | CTD | PMID:28818685 | valproic acid | increases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of EFR3B mRNA | CTD | PMID:23179753 | valproic acid | decreases expression | ISO | EFR3B (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of EFR3B mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFR3B mRNA | CTD | PMID:27188386 | vorinostat | multiple interactions | ISO | EFR3B (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFR3B mRNA | CTD | PMID:27188386 | |